Bayer

Regulus Therapeutics appoints Neil W. Gibson as CSO

Monday, April 18, 2011 01:09 PM

Regulus Therapeutics, a biopharmaceutical company that discovers and develops new medicines targeting microRNAs, has appointed Neil Gibson, Ph.D., as its chief scientific officer. 

More... »

Manning, Chang new appointments at Aileron

Tuesday, April 12, 2011 12:35 PM

CAMBRIDGE, Mass.-based Aileron Therapeutics, a biopharmaceutical company that has developed a new class of drugs called stapled peptides, has appointed Anthony M. Manning, Ph.D., to senior vice president of research and preclinical development and Yong S. Chang, Ph.D., to head of biology.

More... »

Bayer will consolidate in New Jersey

Tuesday, April 5, 2011 02:41 PM

Bayer HealthCare has selected New Jersey as the place to consolidate its East-Coast business site.

More... »

Bayer reports interim results of safety study on oral contraceptives

Tuesday, March 29, 2011 12:59 PM

Bayer HealthCare Pharmaceuticals announced interim results from a large, prospective, observational cohort safety study that offer insights into the increased risk of venous thromboembolism (VTE), or blood clots, which is a well-established risk in women who use combination oral contraceptives (COCs), also known as “the pill.”

More... »

Bayer Healthcare's Stephen Klincewicz speaks on global pharmacovigilance regulations

Friday, March 18, 2011 01:03 PM

Conference producing company marcus evans has interviewed Stephen L. Klincewicz, global head of drug safety for Bayer Consumer Care, in advance of its upcoming Global Pharmacovigilance and Adverse Event Reporting Forum, May 11-13^th in Philadelphia. Klincewicz will be speaking at the conference, which brings together industry executives to examine how to develop innovative methods of signal detection and mitigating adverse events. http://bit.ly/gu9L5E

More... »

FDA approves Bayer's Gadavist injection for MRI

Friday, March 18, 2011 10:32 AM

Bayer HealthCare Pharmaceuticals said the FDA has approved Gadavist (gadobutrol) injection, a macrocyclic gadolinium-based contrast agent (GBCA), for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system (CNS).

More... »